ARUP’s culture of caring has earned it Utah Business magazine’s Best Companies To Work For Award for a fifth consecutive year.
The condition of venous thromboembolism, illustrated here, can be treated using direct oral anticoagulants (DOACs) such as direct factor Xa inhibitors. ARUP’s new chromogenic assays can be used to help assess treatment efficacy.
Routine monitoring of patients taking direct factor Xa inhibitors is not required, but the efficacy and safety of this treatment can be measured with ARUP’s newest test offerings.
ARUP Chief Medical Officer Jonathan Genzen, MD, PhD (left), and Lauren Pearson, DO, MPH, chief medical officer of ARUP at University of Utah Health, are coauthors of a newly published JAMA Research Letter that summarizes results of a survey of clinical labs to evaluate adoption of a new equation to assess kidney function based on creatinine in patient serum. The new equation eliminates adjustment factors for race.
ARUP CMOs are coauthors of a newly published JAMA Research Letter that summarizes how clinical labs are leading the way in eliminating inequality in healthcare.